For research use only. Not for therapeutic Use.
(Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat (HY-139573). Etavopivat is an orally active erythrocyte pyruvate kinase-R (PKR) activator that can be used in studies of sickle cell disease and other haemoglobinopathies[1].
Etavopivat (20 μM, 4 h) improves haemoglobin-oxygen affinity and reduces the sickle point (PoS) in human red blood cells[1].
Etavopivat (oral gavage, 3-22 mg/kg, once daily, 5 days) causes an increase in 2,3-DPG and ATP in crab-eating monkeys at doses of 8 mg/kg and 22 mg/kg[1].
Catalog Number | I042011 |
CAS Number | 2622070-93-1 |
Synonyms | 1-[5-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylsulfonyl)-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrol-2-yl]-3-hydroxy-2-phenylpropan-1-one |
Molecular Formula | C22H23N3O6S |
Purity | ≥95% |
InChI | InChI=1S/C22H23N3O6S/c26-14-19(15-4-2-1-3-5-15)22(27)24-10-16-12-25(13-17(16)11-24)32(28,29)18-8-20-21(23-9-18)31-7-6-30-20/h1-5,8-9,19,26H,6-7,10-14H2 |
InChIKey | KZFFYEPYCVDOGE-UHFFFAOYSA-N |
SMILES | C1COC2=C(O1)C=C(C=N2)S(=O)(=O)N3CC4=C(C3)CN(C4)C(=O)C(CO)C5=CC=CC=C5 |
Reference | [1]. Patricia Schroeder, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. |